vs
豪洛捷（HOLX）与利氏兄弟拍卖行（RBA）财务数据对比。点击上方公司名可切换其他公司
利氏兄弟拍卖行的季度营收约是豪洛捷的1.1倍（$1.2B vs $1.0B），豪洛捷净利率更高（17.1% vs 9.1%，领先8.0%），利氏兄弟拍卖行同比增速更快（5.4% vs 2.5%），豪洛捷自由现金流更多（$215.2M vs $186.5M），过去两年利氏兄弟拍卖行的营收复合增速更高（6.3% vs 1.5%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
利氏兄弟拍卖行（股票代码RBA）是全球知名的工业资产拍卖服务商，注册地位于加拿大，属公开上市企业，总部设在美国伊利诺伊州韦斯特切斯特，普通股同时在多伦多证券交易所与纽约证券交易所挂牌交易。
HOLX vs RBA — 直观对比
营收规模更大
RBA
是对方的1.1倍
$1.0B
营收增速更快
RBA
高出2.9%
2.5%
净利率更高
HOLX
高出8.0%
9.1%
自由现金流更多
HOLX
多$28.7M
$186.5M
两年增速更快
RBA
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.2B |
| 净利润 | $179.1M | $109.7M |
| 毛利率 | 56.0% | — |
| 营业利润率 | 22.6% | 14.7% |
| 净利率 | 17.1% | 9.1% |
| 营收同比 | 2.5% | 5.4% |
| 净利润同比 | -10.9% | -7.4% |
| 每股收益（稀释后） | $0.79 | $0.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXRBA
| Q4 25 | $1.0B | $1.2B | ||
| Q3 25 | $1.0B | $1.1B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $1.0B | $1.1B | ||
| Q4 24 | $1.0B | $1.1B | ||
| Q3 24 | $988.0M | $981.8M | ||
| Q2 24 | $1.0B | $1.1B | ||
| Q1 24 | $1.0B | $1.1B |
净利润HOLXRBA
| Q4 25 | $179.1M | $109.7M | ||
| Q3 25 | $187.2M | $95.5M | ||
| Q2 25 | $194.9M | $109.8M | ||
| Q1 25 | $-17.4M | $113.4M | ||
| Q4 24 | $201.0M | $118.5M | ||
| Q3 24 | $178.6M | $76.1M | ||
| Q2 24 | $194.5M | $111.1M | ||
| Q1 24 | $169.9M | $107.4M |
毛利率HOLXRBA
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — | ||
| Q1 24 | 53.3% | — |
营业利润率HOLXRBA
| Q4 25 | 22.6% | 14.7% | ||
| Q3 25 | 22.6% | 14.5% | ||
| Q2 25 | 24.9% | 15.9% | ||
| Q1 25 | -0.7% | 17.1% | ||
| Q4 24 | 22.5% | 18.1% | ||
| Q3 24 | 23.3% | 15.6% | ||
| Q2 24 | 24.1% | 18.4% | ||
| Q1 24 | 20.7% | 18.7% |
净利率HOLXRBA
| Q4 25 | 17.1% | 9.1% | ||
| Q3 25 | 17.8% | 8.7% | ||
| Q2 25 | 19.0% | 9.3% | ||
| Q1 25 | -1.7% | 10.2% | ||
| Q4 24 | 19.7% | 10.4% | ||
| Q3 24 | 18.1% | 7.8% | ||
| Q2 24 | 19.2% | 10.1% | ||
| Q1 24 | 16.7% | 10.1% |
每股收益（稀释后）HOLXRBA
| Q4 25 | $0.79 | $0.53 | ||
| Q3 25 | $0.84 | $0.43 | ||
| Q2 25 | $0.86 | $0.53 | ||
| Q1 25 | $-0.08 | $0.55 | ||
| Q4 24 | $0.87 | $0.58 | ||
| Q3 24 | $0.75 | $0.36 | ||
| Q2 24 | $0.82 | $0.54 | ||
| Q1 24 | $0.72 | $0.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $531.5M |
| 总债务越低越好 | $2.5B | $2.3B |
| 股东权益账面价值 | $5.2B | $5.6B |
| 总资产 | $9.2B | $12.1B |
| 负债/权益比越低杠杆越低 | 0.48× | 0.42× |
8季度趋势，按日历期对齐
现金及短期投资HOLXRBA
| Q4 25 | $2.4B | $531.5M | ||
| Q3 25 | $2.2B | $674.7M | ||
| Q2 25 | $1.9B | $710.2M | ||
| Q1 25 | $1.6B | $578.1M | ||
| Q4 24 | $2.0B | $533.9M | ||
| Q3 24 | $2.3B | $650.7M | ||
| Q2 24 | $2.4B | $599.5M | ||
| Q1 24 | $2.2B | $462.8M |
总债务HOLXRBA
| Q4 25 | $2.5B | $2.3B | ||
| Q3 25 | $2.5B | $2.6B | ||
| Q2 25 | $2.5B | $2.6B | ||
| Q1 25 | $2.5B | $2.6B | ||
| Q4 24 | $2.5B | $2.6B | ||
| Q3 24 | $2.5B | $2.7B | ||
| Q2 24 | $2.5B | $2.8B | ||
| Q1 24 | $2.6B | $2.9B |
股东权益HOLXRBA
| Q4 25 | $5.2B | $5.6B | ||
| Q3 25 | $5.0B | $5.5B | ||
| Q2 25 | $4.8B | $5.5B | ||
| Q1 25 | $4.6B | $5.3B | ||
| Q4 24 | $4.8B | $5.2B | ||
| Q3 24 | $5.1B | $5.2B | ||
| Q2 24 | $5.0B | $5.2B | ||
| Q1 24 | $4.8B | $5.1B |
总资产HOLXRBA
| Q4 25 | $9.2B | $12.1B | ||
| Q3 25 | $9.0B | $12.2B | ||
| Q2 25 | $8.8B | $12.2B | ||
| Q1 25 | $8.5B | $11.9B | ||
| Q4 24 | $8.7B | $11.8B | ||
| Q3 24 | $9.2B | $11.9B | ||
| Q2 24 | $8.9B | $12.1B | ||
| Q1 24 | $8.7B | $12.0B |
负债/权益比HOLXRBA
| Q4 25 | 0.48× | 0.42× | ||
| Q3 25 | 0.50× | 0.47× | ||
| Q2 25 | 0.52× | 0.47× | ||
| Q1 25 | 0.55× | 0.50× | ||
| Q4 24 | 0.53× | 0.50× | ||
| Q3 24 | 0.49× | 0.52× | ||
| Q2 24 | 0.51× | 0.55× | ||
| Q1 24 | 0.53× | 0.58× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | $255.2M |
| 自由现金流经营现金流 - 资本支出 | $215.2M | $186.5M |
| 自由现金流率自由现金流/营收 | 20.5% | 15.5% |
| 资本支出强度资本支出/营收 | 1.4% | 5.7% |
| 现金转化率经营现金流/净利润 | 1.28× | 2.33× |
| 过去12个月自由现金流最近4个季度 | $1.0B | $719.2M |
8季度趋势，按日历期对齐
经营现金流HOLXRBA
| Q4 25 | $229.9M | $255.2M | ||
| Q3 25 | $355.1M | $239.7M | ||
| Q2 25 | $343.3M | $326.5M | ||
| Q1 25 | $169.4M | $156.8M | ||
| Q4 24 | $189.3M | $184.5M | ||
| Q3 24 | $367.0M | $285.4M | ||
| Q2 24 | $405.8M | $337.3M | ||
| Q1 24 | $292.4M | $124.8M |
自由现金流HOLXRBA
| Q4 25 | $215.2M | $186.5M | ||
| Q3 25 | $341.4M | $188.5M | ||
| Q2 25 | $330.5M | $241.7M | ||
| Q1 25 | $153.9M | $102.5M | ||
| Q4 24 | $172.5M | $127.9M | ||
| Q3 24 | $350.6M | $248.5M | ||
| Q2 24 | $385.3M | $308.6M | ||
| Q1 24 | $279.6M | $79.6M |
自由现金流率HOLXRBA
| Q4 25 | 20.5% | 15.5% | ||
| Q3 25 | 32.5% | 17.3% | ||
| Q2 25 | 32.3% | 20.4% | ||
| Q1 25 | 15.3% | 9.2% | ||
| Q4 24 | 16.9% | 11.2% | ||
| Q3 24 | 35.5% | 25.3% | ||
| Q2 24 | 38.1% | 28.2% | ||
| Q1 24 | 27.5% | 7.5% |
资本支出强度HOLXRBA
| Q4 25 | 1.4% | 5.7% | ||
| Q3 25 | 1.3% | 4.7% | ||
| Q2 25 | 1.3% | 7.2% | ||
| Q1 25 | 1.5% | 4.9% | ||
| Q4 24 | 1.6% | 5.0% | ||
| Q3 24 | 1.7% | 3.8% | ||
| Q2 24 | 2.0% | 2.6% | ||
| Q1 24 | 1.3% | 4.2% |
现金转化率HOLXRBA
| Q4 25 | 1.28× | 2.33× | ||
| Q3 25 | 1.90× | 2.51× | ||
| Q2 25 | 1.76× | 2.97× | ||
| Q1 25 | — | 1.38× | ||
| Q4 24 | 0.94× | 1.56× | ||
| Q3 24 | 2.05× | 3.75× | ||
| Q2 24 | 2.09× | 3.04× | ||
| Q1 24 | 1.72× | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
RBA
| Buyer Revenue | $577.2M | 48% |
| Seller Revenue | $255.2M | 21% |
| CA | $199.0M | 17% |
| Other | $124.7M | 10% |
| AU | $47.3M | 4% |
